Tevard Biosciences

Tevard Biosciences is developing a new gene therapy platform to target Dravet syndrome and other rare diseases with unmet needs. Our primary central nervous system indication is Dravet syndrome, and we are currently employing a dual approach: stabilizing mRNA to increase the expression of healthy copies of SCN1A, and correcting the defective copies of the gene through codon suppression (when mutations create premature stop codons).